All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Six months later than first expected, FDA approval for Amgen Inc.'s secondary hyperparathyroidism (SHPT) treatment, Parsabiv (etelcalcetide), has arrived.
